Change of Substantial Shareholding
RNS Number : 0946NSabien Technology Group PLC27 January 2021
This announcement contains inside information as stipulated under the UK Market Abuse Regulations (“MAR”).
27 January 2021
Sabien Technology Group plc
(“Sabien” or the “Company”)
Change of Substantial Shareholding
Further to the announcement by the Company on 22 January 2021, and the termination of the Company’s proposed acquisition of the entire issued share capital of Ptarmigan Health Destinations SA, the Board of Sabien announces that it has been informed by the Company’s largest shareholder, PSF Private Markets, that it has sold its entire shareholding in the Company.
This holding of 363,418,290 shares, representing 25.00% of the issued share capital of the Company, has been placed by the Company’s Broker, Peterhouse Capital Limited, with a range of its investor clients, at a price of £0.001175p per share.
For further information:
| Sabien Technology Group plcRichard Parris, Executive Chairman | +44 20 7993 3700 |
| Allenby Capital Limited (Nominated Adviser)John Depasquale / Asha Chotai | +44 203 328 5656 |
| Peterhouse Capital Limited (Broker)Duncan Vasey / Lucy Williams | +44 207 469 0930 |
| The person who arranged for the release of this announcement on behalf of the Company was Richard Parris, Executive Chairman. A copy of this announcement will be available from the Company’s website at www.sabien.com . |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
